(Q58024833)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Michael Millward

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Paul Mainwaring

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Ted Logan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Anna Pavlick

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Ahmad A Tarhini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Steven J Kathman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Kevin H Laubscher

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Mohammed M Dar

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

John M Kirkwood

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

English

0 references

publication date

1 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

number of pages

10

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

859-868

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Interleukin-18 in combination with IL-2 enhances natural killer cell activity without inducing large amounts of IFN-gamma in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Interleukin-18 acts as an angiogenesis and tumor suppressor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Overview of interleukin-18: more than an interferon-gamma inducing factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.24100

1 reference

7 January 2021

SYNERGISTIC PROLIFERATION AND ACTIVATION OF NATURAL KILLER CELLS BY INTERLEUKIN 12 AND INTERLEUKIN 18

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Clinical trial designs for cytostatic agents: are new approaches needed?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Combined Stimulation with Interleukin-18 and CpG Induces Murine Natural Killer Dendritic Cells to Produce IFN-γ and Inhibit Tumor Growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24100

7 January 2021

Identifiers

DOI

10.1002/CNCR.24100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19140204%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference